Skip to main content
2023 Battelle Distinguished Inventors

Four scientists affiliated with ORNL were named Battelle Distinguished Inventors during the lab’s annual Innovation Awards on Dec. 1 in recognition of being granted 14 or more United States patents.

UKAEA will provide novel fusion materials to be irradiated in ORNL’s HFIR facility over the next four years. From left, Kathy McCarthy, Jeremy Busby, Mickey Wade, Prof Sir Ian Chapman (UKAEA CEO), Cynthia Jenks and Yutai Kato will represent this new partnership. Not pictured: Dr. Amanda Quadling, UKAEA’s Director of Materials Research Facility. Credit: Genevieve Martin/ORNL, U.S. Dept. of Energy

ORNL has entered a strategic research partnership with the United Kingdom Atomic Energy Authority, or UKAEA, to investigate how different types of materials behave under the influence of high-energy neutron sources. The $4 million project is part of UKAEA's roadmap program, which aims to produce electricity from fusion.

Using as much as 50 percent lignin by weight, a new composite material created at ORNL is well suited for use in 3D printing.

Scientists at the Department of Energy’s Oak Ridge National Laboratory have created a recipe for a renewable 3D printing feedstock that could spur a profitable new use for an intractable biorefinery byproduct: lignin.

Infected Poplar

Scientists studying a valuable, but vulnerable, species of poplar have identified the genetic mechanism responsible for the species’ inability to resist a pervasive and deadly disease. Their finding, published in the Proceedings of the National Academy of Sciences, could lead to more successful hybrid poplar varieties for increased biofuels and forestry production and protect native trees against infection.

Radiochemical technicians David Denton and Karen Murphy use hot cell manipulators at Oak Ridge National Laboratory during the production of actinium-227.

The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.